Questions
Questions people bring to MD Sermorelin
Some short answers, including the antibody question that sent me looking through the childhood papers.
Do antibodies stop sermorelin from working?
The childhood findings resist a simple answer. Chen and colleagues found GHRH antibodies in nearly all participants without a correlation with growth. Lanes and Carrillo detected antibodies in several responders without apparent interference with growth. Antibody detection and loss of clinical response need separate investigation.
Does sermorelin improve sleep?
Anecdotal accounts often emphasize deeper rest and vivid dreams. In the Vitiello trial in 89 older adults, GH secretion doubled but slow-wave sleep architecture did not significantly change. The prominence of a sleep benefit in forum accounts has outrun the confidence I can place in the measured sleep findings.
Can the pituitary response fade?
Yes, a continuous-infusion study in children reported an initial increase followed by declining GH output over months, including complete suppression in one child. Longer childhood studies using daily administration reported continuing growth responses. Exposure pattern matters; a blanket assertion of “no tolerance” loses that difference.
Former FDA approvals
Sermorelin had FDA approvals for diagnostic use in 1990 and pediatric idiopathic GH-deficiency treatment in 1997. Commercial production ended in 2008 for business reasons; the formal withdrawal notice followed in 2013. The pediatric review documents the clinical history. Current U.S. prescribing uses a compounded preparation without FDA approval, subject to an individual clinician’s decision.
Can adult trials answer a height question?
The adult studies discussed here measured hormones, body composition, strength or cognition. The childhood growth trial enrolled GH-deficient children. I need an appropriate population before I can attach a result to a hope about height. The children’s growth section gives that evidence its proper setting.
WADA restrictions
The 2025 WADA Prohibited List names sermorelin under S2.2.4, growth hormone-releasing factors, prohibited in and out of competition. This sport restriction applies separately from the U.S. prescription and compounding framework.